dichloro(4- cymene)(1,3,5- triaza- 7- phosphatricyclo(3.3.1.1)decane)ruthenium(II)

has antineoplastic activity; structure in first source

Also Known As:

RAPTA-C; dichloro(p-1-methyl-3-isopropylbenzene)(1,3,5-triaza-7-phosphatricyclo(3.3.1.1)decane)ruthenium(II); dichloro(p-cymene)(1,3,5-triaza-7-phosphatricyclo(3.3.1.1)decane)ruthenium(II)

Networked: 13 relevant articles (4 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Terpenes: 1461
    - Monoterpenes: 522
      - Cymenes: 15
        dichloro(4-cymene)(1,3,5-triaza-7-phosphatricyclo(3.3.1.1)decane)ruthenium(II): 13
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Cymenes: 15
        dichloro(4-cymene)(1,3,5-triaza-7-phosphatricyclo(3.3.1.1)decane)ruthenium(II): 13
- Organometallic Compounds: 64
  - dichloro(4-cymene)(1,3,5-triaza-7-phosphatricyclo(3.3.1.1)decane)ruthenium(II): 13

Experts

1.	Dyson, Paul J: 5 articles (01/2017 - 09/2008)
2.	Stenzel, Martina H: 4 articles (03/2019 - 12/2013)
3.	Lu, Mingxia: 3 articles (03/2019 - 03/2016)
4.	Lu, Hongxu: 3 articles (10/2017 - 12/2013)
5.	Biancalana, Lorenzo: 2 articles (02/2021 - 12/2017)
6.	Marchetti, Fabio: 2 articles (02/2021 - 12/2017)
7.	Berndsen, Robert H: 2 articles (01/2017 - 03/2015)
8.	Griffioen, Arjan W: 2 articles (01/2017 - 03/2015)
9.	Nowak-Sliwinska, Patrycja: 2 articles (01/2017 - 03/2015)
10.	Weiss, Andrea: 2 articles (01/2017 - 03/2015)

Related Diseases

1.	Neoplasms (Cancer) 03/26/2019 - "We observed that RAPTA-C showed low general toxicity to both primary healthy and cancer cell lines. " 09/01/2008 - "Consequently, RAPTA-C treatment results in a significant inhibition in the progression of cancer in an animal model, which emulates the human disease, and does so with remarkably low general toxicity; hence, RAPTA-C has potential for clinical application." 09/01/2008 - "RAPTA-C exhibits effective cell growth inhibition by triggering G(2)/M phase arrest and apoptosis in cancer cells. " 03/01/2016 - "RAPTA-C micelles selectively targeted the metastatic tumor cells over the nontumorigenic CHO cells. " 03/01/2016 - "Further improvement of the RAPTA-C delivery vehicle may provide useful tools to harness ruthenium compounds for metastatic cancer therapy. "
2.	Breast Neoplasms (Breast Cancer) 05/01/2010 - "In vitro ruthenation of human breast cancer suppressor gene 1 (BRCA1) by the antimetastasis compound RAPTA-C and its analogue CarboRAPTA-C." 01/01/2023 - "The dual drug delivery system was studied via in vitro tests using MDA-MB-231 breast cancer cells and it was observed that RAPTA-C in combination with PTX significantly enhanced anti-tumour and anti-metastasis activity." 03/01/2016 - "RAPTA-C conjugated micelles showed an improved anti-metastatic effect compared with RAPTA-C for 2D cultured breast tumor cells. " 10/01/2017 - "As a result, fructose-coated nanoparticles can be a promising drug delivery platform of RAPTA-C for the treatment of metastatic breast cancer." 03/01/2016 - "Important in particular is that the effect is more pronounced in cancerous breast cancer cells while RAPTA-C delivered in micelles does not seem to show any effect on healthy cells. "
3.	Infections 02/15/2021 - "Here, we evaluate the efficacy of well defined, easily available and robust ruthenium(II) η6-arene compounds on 3D models of HNSCCs with or without human papillomavirus (HPV) infection and compare their effects to the state-of-the-art RAPTA-C, a promising ruthenium compound with known anti-cancer activity. "
4.	Ovarian Neoplasms (Ovarian Cancer) 12/09/2013 - "RAPTA-C conjugation, micellization, and subsequent cytotoxicity and cell uptake of these polymeric moieties was tested on ovarian cancer A2780, A2780cis, and Ovcar-3 cell lines. " 03/26/2019 - "RAPTA-C did not affect adhesion of OVCAR4 ovarian cancer cells; however, it significantly inhibited invasion of these cells within the omentum model, either in its free form or as cargos inside the micelles. " 03/26/2019 - "Ovarian cancer cell adhesion and invasion into a model of omentum were analyzed with and without RAPTA-C conjugated micelles in a range of conditions. " 03/26/2019 - "A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles." 10/14/2010 - "The complexes showed a cytotoxic effect on human ovarian cancer cells and were markedly more active than their Ti or Ru monometallic analogues titanocene dichloride and RAPTA-C, respectively. "
5.	Neoplasm Metastasis (Metastasis) 01/01/2023 - "The dual drug delivery system was studied via in vitro tests using MDA-MB-231 breast cancer cells and it was observed that RAPTA-C in combination with PTX significantly enhanced anti-tumour and anti-metastasis activity." 03/26/2019 - "The ability to inhibit metastasis of RAPTA-C delivered in fructose coated nanoparticles was investigated for the first time via this model. " 03/26/2019 - "Therefore we aimed to investigate the anti-metastatic properties of RAPTA-C conjugated micelles in ovarian cancer metastasis. " 10/01/2017 - "The ruthenium complex-dichlororuthenium (II) (p-cymene) (1,3,5-triaza-7-phosphaadamantane) (RAPTA-C)-has shown to be remarkably effective at suppressing the growth of solid tumor metastases. "

Related Drugs and Biologics

1.	4-cymene (p-cymene)
2.	Ruthenium
3.	Micelles
4.	Carboplatin (JM8)
5.	Organometallic Compounds
6.	Cisplatin (Platino)
7.	Fructose
8.	Ruthenium Compounds
9.	Paclitaxel (Taxol)
10.	Drug Carriers

Related Therapies and Procedures

1.	Therapeutics
2.	Photochemotherapy (Photodynamic Therapy)